A Phase 2/3 interventional study of HMPL-523(300mg PO QD) and Placebo in Warm Antibody Autoimmune Hemolytic Anemia, sponsored by Hutchmed. Active, not recruiting at 39 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Hutchmed · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Anemia, Hemolytic, Autoimmune with a site in China — 22 open to participants now, 30 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · China.
Among the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China, this one is the 4th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 2/3, reaches primary completion later than 7 of the 29 other live ones, and was the 9th registered.
103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.
Browse Anemia, Hemolytic, Autoimmune studies →22 of the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China are open now. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Juventas Cell Therapy Ltd. · Sites in China
Ages 18–75
Circunited BioPharma (Shenzhen) Co., Ltd. · Sites in China
Ages 18–60
The Second Hospital of Anhui Medical University · Sites in China
Ages 10+
Peking Union Medical College Hospital · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 11 · Phase 3 4 · Phase 4 1
First in 2001; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Median enrollment 18 across the 35 interventional studies, 1,312 across the 4 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hutchmed, one of the names counted as HUTCHMED. Under that name alone:
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
HUTCHMED has 1 study filed under Anemia, Hemolytic, Autoimmune — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia, Hemolytic, Autoimmune with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06733610Institute of Hematology & Blood Diseases Hospital, ChinaCAR T-cell Therapy Targeting CD19 and BCMA in Patients With AIHA Who Have Failed ≥3 Lines of Therapy. | 2027-01-12 |
| NCT07453368Peking Union Medical College HospitalOrelabrutinib in the Treatment of Relapsed/Refractory AIHA | 2027-03-01 |
| NCT07453836China Immunotech (Beijing) Biotechnology Co., Ltd.Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia | 2027-03-18 |
| NCT06978738Changzhou No.2 People's HospitalUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | 2027-05 |
| NCT07689604Institute of Hematology & Blood Diseases Hospital, ChinaMETA 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients with wAIHA.
Phase III Study(Part A): Confirmation of Efficacy safety and of HMPL-523 in adult patients with wAIHA.
Phase III Study (Part B): To further evaluate the long-term safety and tolerability of HMPL-523 in adult patients with wAIHA.
Phase II Study: An eight-week randomized, placebo-controlled, double-blind phase followed by at least a 16-week open-label HMPL-523 treatment to evaluate the safety and preliminary efficacy of HMPL-523. The primary endpoint was the proportion of patients with overall Hb response by week 24.
Phase III study (Part A):A 24-week randomized, placebo-controlled double-blind phase to evaluate efficacy and safety of HMPL-523. The primary endpoint was the proportion of patients who achieve a durable response during weeks 5 to 24.
Phase III Study (Part B): An open-label Phase evaluating long-term safety and efficacy of HMPL-523 treatment. Eligible patients include those with lack of efficacy during the 20-week Phase III Part A treatment, completion of the Phase II study, or completion of 24-week Phase III Part A treatment with investigators assessment of potential benefit from open-label treatment with HMPL-523.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase II: Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 8 weeks and at least 16 weeks open-label treatment. Phase III: Part A (Randomized, Double-Blind Phase): Eligible subjects will receive 300 mg HMPL-523 treatment once daily for 24 weeks. Part B (Open-label Phase): Eligible subjects will roll-over into the open-label phase and receive treatment with HMPL-523 at the same dose administered after 24-week randomized controlled trial phase (Part A) or in Phase II. Treatment will continue until 24 weeks after the last subject is enrolled in Part B.
Drug: HMPL-523(300mg PO QD)
Phase II: Eligible subjects will receive 300 mg HMPL-523 matched placebo treatment once daily for 8 weeks. Phase III: Part A (Randomized, Double-Blind Phase): Eligible subjects will receive 300 mg HMPL-523 matched placebo treatment once daily for 24 weeks.
Drug: Placebo
HMPL-523(300mg PO QD)
Also known as: Sovleplenib
Placebo(300mg PO QD)
Phase II: Overall Hb response rate
Phase II: Overall Hb response rate: The proportion of patients with overall Hb response by Week 24
Time frame: 24Weeks
Phase III(Part A): Durable Hb response rate
Phase III(Part A):Durable Hb response rate: The proportion of patients who achieve a durable response by Week 24 during Part A
Time frame: 24Weeks
Phase II: Overall Hb response rate
Phase II: Overall Hb response rate: the proportion of patients with overall Hb response by Week 8
Time frame: 8 Weeks
Phase II: Durable Hb response rate
Phase II: Durable Hb response rate: the proportion of patients who achieve a durable response by Week 24.
Time frame: 24 Weeks
Phase II: Median change in Hb
Phase II: Median change from baseline in Hb at Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Effects on reticulocyte count
Phase II: Change from baseline in reticulocyte count at Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Effects on lactate dehydrogenase
Phase II: Change from baseline in lactate dehydrogenase(LDH) at Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Effects on haptoglobin
Phase II: Change from baseline in haptoglobin at Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Effects on total bilirubin(TBIL)
Phase II: Change from baseline in total bilirubin(TBIL) at Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Proportion of rescue therapy
Phase II: Proportion of patients who received rescue therapy by Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Proportion of patients with dose reduction in baseline anti-wAIHA medications
Phase II: Proportion of patients who had a dose reduction in glucocorticoids or other baseline concomitant anti-wAIHA medications by Weeks 8 and 24 of treatment.
Time frame: 24 Weeks
Phase II: Time to response
Phase II: Time to response
Time frame: 24 Weeks
Phase II: Effect of study treatment on patient fatigue
Phase II: Evaluation of the effect of study treatment on fatigue at Weeks 8 and 24, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
Time frame: 24 Weeks
Phase II: Effect of study treatment on quality of life
Phase II: Evaluation of the effect of study treatment on quality of life at Weeks 8 and 24, as assessed by the 36-Item Short Form Health Survey (SF-36).
Time frame: 24 Weeks
Phase III(Part A): Overall Hb response rate
Phase III(Part A): Proportion of patients who achieved an overall Hb response during the 20-week and 24-week double-blind treatment periods(defined as at least one Hb value ≥100g/L with an increase of at least 20g/L from baseline, not attributable to rescue therapy).
Time frame: 24 Weeks
Phase III(Part A): Median change in Hb
Phase III(Part A): Median change from baseline in Hb during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III(Part A): Effects on reticulocyte count
Phase III(Part A): Change from baseline in reticulocyte count during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III(Part A): Effects on lactate dehydrogenase
Phase III(Part A): Change from baseline in lactate dehydrogenase(LDH) during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III(Part A): Effects on haptoglobin
Phase III(Part A): Change from baseline in haptoglobin during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III(Part A): Effects on total bilirubin(TBIL)
Phase III(Part A): Change from baseline in total bilirubin(TBIL) during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III(Part A): Proportion of rescue therapy
Phase III(Part A): Proportion of patients who received protocol-defined rescue therapy during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III (Part A): Proportion of patients reducing or discontinuing baseline anti-wAIHA medications
Phase III(Part A):The proportion of patients who reduced or discontinued glucocorticoids or other baseline concomitant anti-wAIHA medications during the 20-week and 24-week double-blind treatment periods.
Time frame: 24 Weeks
Phase III(Part A): Time to first response
Phase III(Part A): Time to first response
Time frame: 24 Weeks
Phase III(Part A): Duration of durable response
Phase III(Part A): Duration of durable response
Time frame: 24 Weeks
Phase III(Part A): Cumulative duration of response
Phase III(Part A): Cumulative duration of response
Time frame: 24 Weeks
Phase III(Part A): Effect of study treatment on patient fatigue
Phase III(Part A): Effect of study treatment on patient fatigue during the 20-week and 24-week treatment periods, as assessed by the FACIT-F score (40 items; range, 0-160), including the FACIT-Fatigue subscale (13 items; range, 0-52).
Time frame: 24 Weeks
Phase III(Part A): Effect of study treatment on patients' quality
Phase III(Part A): Effect of study treatment on patients' quality of life during the 20-week and 24-week treatment periods, as assessed by SF-36.
Time frame: 24 Weeks
Incidence of Treatment-emergent Adverse Events (TEAEs)
Incidence of treatment-emergent adverse events (TEAEs) assessed according to NCI CTCAE Version 5.0.
Time frame: 36 Months
Phase II:Efficacy in patients with DAT positivity confirmed by the central laboratory
Phase II: Assessed by overall Hb response rate and durable response rate.
Time frame: 24 Weeks
Phase III(Part B): Durable Hb response rate
Phase III(Part B): Durable Hb response rate: the proportion of patients who achieve a durable response during Part B.
Time frame: 30 Months
Plan to share: Yes — The results of this study can be published in core journals or international scientific conferences, and the primary investigators who make significant contributions to the implementation and management of this study and the personnel who makes great contributions to the design, interpretation or analysis of this study (such as the staffs or consultants of the sponsor) can have their authorship attribution. The sponsor promises to provide the manuscript to the investigator for review before publication of any result of the study. Investigators have to obtain the approval of the sponsor before submitting academic articles or abstracts. The study personnel have the right to publish results of this study, however, the requirement of protecting confidential information must be met. The confidential information is the property of the sponsor only, cannot be disclosed to others without the written approval of the sponsor, and cannot be used for other purposes.
Supporting information: Study protocol, Informed consent form, Clinical study report
Ran from Sep 2022 to primary completion in Nov 2025, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sovleplenib
Anemia, Hemolytic, Autoimmune →